Regeneron Pharmaceuticals (REGN) Asset Writedowns and Impairment (2010 - 2015)

Regeneron Pharmaceuticals' Asset Writedowns and Impairment history runs 5 years deep, the most recent figure standing at $387000.0 for Q2 2015.

• On a quarterly basis, Asset Writedowns and Impairment fell 92.19% year-over-year to $387000.0 in Q2 2015; TTM through Jun 2015 was $9.9 million, a 56.11% decrease from a year earlier, with the FY2014 full-year figure at $18.1 million, down 21.72% from the prior year.
• Asset Writedowns and Impairment eased to $387000.0 in Q2 2015 per REGN's latest filing, from $2.4 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $6.0 million in Q3 2013 and bottomed at $250000.0 in Q2 2011.
• The 4-year median for Asset Writedowns and Impairment is $4.8 million (2014), against an average of $3.5 million.
• Across the five-year window, Asset Writedowns and Impairment climbed 28.39% in 2011 and plunged 92.19% in 2015, its largest moves.
• Year by year, Asset Writedowns and Impairment stood at $1.3 million in 2011, then surged by 345.69% to $5.7 million in 2013, then plunged by 57.82% to $2.4 million in 2014, then slumped by 84.03% to $387000.0 in 2015.
• Per Business Quant, the three latest REGN Asset Writedowns and Impairment figures stand at $387000.0 (Q2 2015), $2.4 million (Q1 2015), and $2.4 million (Q4 2014).